210
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Prognostic Factors of Adrenocortical Carcinoma: Experience from a Regional Medical Center in Eastern China

, , , & ORCID Icon
Pages 453-465 | Received 28 Nov 2022, Accepted 24 Jan 2023, Published online: 03 Feb 2023

References

  • Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282–326. doi:10.1210/er.2013-1029
  • Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579–2586. doi:10.1016/j.ejca.2013.02.034
  • Asare EA, Wang TS, Winchester DP, et al. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery. 2014;156(6):1378–1385. doi:10.1016/j.surg.2014.08.018
  • Puglisi S, Perotti P, Cosentini D, et al. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert Rev Anticancer Ther. 2018;18(11):1125–1133. doi:10.1080/14737140.2018.1510325
  • Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):221–226. doi:10.1097/MED.0b013e3282fdf4c0
  • Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–2197. doi:10.1056/NEJMoa1200966
  • Alyateem G, Nilubol N. Current status and future targeted therapy in adrenocortical cancer. Front Endocrinol. 2021;12:613248. doi:10.3389/fendo.2021.613248
  • Erdogan I, Deutschbein T, Jurowich C, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181–191. doi:10.1210/jc.2012-2559
  • McDuffie LA, Aufforth RD. Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol. 2016;3(2):161–174. doi:10.2217/ije-2015-0003
  • Gaujoux S, Mihai R, Carnaille B. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104(4):358–376. doi:10.1002/bjs.10414
  • Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702. doi:10.6004/jnccn.2018.0056
  • Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169(6):891–899. doi:10.1530/EJE-13-0519
  • Şişman P, Şahin AB, Peynirci H, et al. Adrenocortical carcinoma: single center experience. Turk J Urol. 2017;43(4):462–469. doi:10.5152/tud.2017.81598
  • Berruti A, Fassnacht M, Haak H, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65(4):832–838. doi:10.1016/j.eururo.2013.11.006
  • Amini N, Margonis GA, Kim Y, et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23(1):126–133. doi:10.1245/s10434-015-4810-y
  • Cobb WS, Kercher KW, Sing RF, Heniford BT. Laparoscopic adrenalectomy for malignancy. Am J Surg. 2005;189(4):405–411. doi:10.1016/j.amjsurg.2005.01.021
  • Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005;138(6):1078–1085. doi:10.1016/j.surg.2005.09.012
  • Donatini G, Caiazzo R, Do Cao C, et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol. 2014;21(1):284–291. doi:10.1245/s10434-013-3164-6
  • Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158–1164. doi:10.1016/j.surg.2012.08.014
  • Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34(6):1380–1385. doi:10.1007/s00268-010-0532-2
  • Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150–1157. doi:10.1016/j.surg.2012.08.024
  • Kerkhofs TM, Ettaieb MH, Hermsen IG, Haak HR. Developing treatment for adrenocortical carcinoma. Endocr Relat Cancer. 2015;22(6):R325–338. doi:10.1530/ERC-15-0318
  • Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol. 2004;16(1):13–18. doi:10.1097/00001622-200401000-00004
  • Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872–878. doi:10.1007/s00268-005-0329-x
  • Hermsen IG, Haak HR, de Krijger RR, et al. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. Eur J Endocrinol. 2013;169(1):51–58. doi:10.1530/EJE-13-0093
  • Hermsen IG, Groenen YE, Dercksen MW, Theuws J, Haak HR. Response to radiation therapy in adrenocortical carcinoma. J Endocrinol Invest. 2010;33(10):712–714. doi:10.1007/BF03346675
  • Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6(8):719–726. doi:10.1007/s10434-999-0719-7
  • Vaidya A, Nehs M, Kilbridge K. Treatment of adrenocortical carcinoma. Surg Pathol Clin. 2019;12(4):997–1006. doi:10.1016/j.path.2019.08.010
  • Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115(2):243–250. doi:10.1002/cncr.24030
  • Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99(2):455–461. doi:10.1210/jc.2013-2856
  • Baechle JJ, Marincola Smith P, Solórzano CC, et al. Cumulative GRAS score as a predictor of survival after resection for adrenocortical carcinoma: analysis from the U.S. adrenocortical carcinoma database. Ann Surg Oncol. 2021;28(11):6551–6561. doi:10.1245/s10434-020-09562-8
  • Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26(10):2119–2125. doi:10.1093/annonc/mdv329
  • Liang J, Liu Z, Zhou L, et al. The clinical utility of ‘GRAS’ parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution. Endocrine. 2020;67(2):449–456. doi:10.1007/s12020-019-02141-2
  • Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association Of Endocrine Surgeons study group. World J Surg. 2001;25(7):891–897. doi:10.1007/s00268-001-0047-y